Why Kezar Life Sciences Stock Is Crushing It Today

Why Kezar Life Sciences Stock Is Crushing It Today

Shares of the clinical-stage biotech Kezar Life Sciences (NASDAQ: KZR) are soaring this morning following a positive mid-stage data readout for its lupus nephritis candidate zetomipzomib. This potentially deadly autoimmune disorder is characterized by swelling of the kidneys in patients with systemic lupus erythematosus. What appears to be driving this massive uptick in Kezar's shares today is the drug's 65% overall renal response among patients who reached the end of treatment.